Business Context and Reporting Period
This Form 8-K was filed by Halozyme Therapeutics, Inc. on June 3, 2015. The filing reports significant changes in executive leadership, specifically the appointment of a new Chief Financial Officer and the retirement of the incumbent.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Appointment of CFO: Laurie Stelzer was appointed Senior Vice President and Chief Financial Officer, effective June 15, 2015.
- Departure of CFO: David A. Ramsay resigned as Vice President and Chief Financial Officer, effective June 15, 2015, to retire.
- Compensation Package for Ms. Stelzer:
- Annual Salary: $420,000
- First-Year Bonus Target: 40% of prorated base salary
- Stock Options: 225,000 shares
- Restricted Stock Units (RSUs): 27,500 shares
- Relocation Assistance: $150,000
- Sign-on Bonus: $50,000
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business strategy. No specific risks or contingencies were disclosed in this report, other than the standard transition of responsibilities between the outgoing and incoming CFO.
Investor Verification Checklist
- Verify the effective date of the CFO transition (June 15, 2015).
- Review the vesting schedule for the 225,000 stock options and 27,500 RSUs granted to Ms. Stelzer (standard four-year schedule).
- Confirm the total immediate cash outlay for the new CFO ($200,000 in relocation and sign-on bonus).
- Check for any subsequent filings regarding the departure of Mr. Ramsay or the integration of Ms. Stelzer.